Results of a multicenter controlled study of a hypolipidemic drug polycosanol in Russia

Terapevticheskii Arkhiv

Volumn 72, Issue 12, 2000, Pages 8-10

  Nikitin, Yu P ^a   Slepchenko, N V ^a   Gratsiansky, N A ^a   Nechaev, A S ^a   Syrkin, A L ^a   Poltavskaya, M G ^a   Sumarokov, A V ^a   Revazov, A V ^a  

^a NONE

Author keywords

Besafibrate; Hypercholesterolemia; Polycosanol; Treatment

Indexed keywords

1 OCTACOSANOL; 1-OCTACOSANOL; ANTILIPEMIC AGENT; FATTY ALCOHOL;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYPERLIPOPROTEINEMIA TYPE 2; MALE; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RUSSIAN FEDERATION;

ANTILIPEMIC AGENTS; DOUBLE-BLIND METHOD; FATTY ALCOHOLS; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; RUSSIA;

EID: 24044444613     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Pyorala K. et al. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur. Heart J. 1994; 15: 1300-1331.
2. Shepherd J., Cobbe S., Ford I. et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. 1995; 333: 1301-1307.
3. Scandinavian Simvastatin Survival Group. Randomized trail of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
4. Jucema J. W., Bruschke A. V. G., Van Boven A. J. et al. Effects of lipid-lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995; 91: 2528-2540.
5. Salonen R., Nyyssonen K., Parkkala-Sarataho E., Salonen J. T. The Kuopio Atherosclerosis Prevention Study (KAPS): effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. Am. J. Cardiol. 1995; 76: 34-39.
6. Rubins H., Robins S. et al. Distribution of lipids in 8500 men with coronary artery disease. Am. J. Cardiol. Ibid. 75: 1196-1201.
7. Menendez R., Fernandaz I., Del Rio A. et al. Polycosanol inhibits cholesterol biosynthesis and enhances LDL processing in cultures human fibroblasts. Biol. Res. 1994; 27: 199-203.
8. Hernandez E., Illnait J., Mas R. et al. Effects of polycosanol in serum lipids and lipoproteins in healthy volunteers. Curr. Ther. Res. 1992; 51: 568-575.
9. Aneiros E., Calderon B., Mas R. et al. Effects of successive dose increases of polycosanol on the lipid profile and tolerability of treatment. Curr. Ther. Res. Ibid. 1993; 54: 304-312.
10. Aneiros E., Mas R., Calderon B. et al. Effect of polycosanol in lowering-cholesterol levels in patients with hypercholesterolemia. Curr. Ther. Res. Ibid. 1995; 56: 176-182.
11. Canetti M., Moreira M., Illnait J. et al. One-year study on the effect of polycosanol (5mg-twice-a-day) on lipid profile in patients with type II hypercholesterolemia. Adv. Ther. 1995; 12: 245-254.
12. Canetti M., Moreira M., Illnait J. et al. A two-year study on the efficacy and tolerabilily of polycosanol in patients with type II hypercholesterolemia. J. Clin. Pharmacol. Res. 1995; 15: 159-165.
13. Castano G., Mas R., Nodarse M. et al. One-year study on the efficacy and safety of polycosanol (5 mg twice day) in the treatment of type II hypercholesterolemia. Curr. Ther. Res. 1995; 56: 296-304.
14. Castano G., Canetti M., Moreira M. et al. The efficacy and tolerability of polycosanol (10 mg/day) in elderly patients with type II hypercholesterolemia: A one-year study. Curr. Ther. Res. Ibid. 819-828.
15. Pons P., Rodriguez M., Robana C. et al. Effects of polycosanol successive dose increases in lipid profile of patients with type II hypercholesterolemia and tolerability to treatment. J. Clin. Pharmacol. Res. 1994; 14: 27-33.
16. Soltero I., Fuenmayor I., Colmenares J. Estudio comparative doble ciego de la eficacia y tolerancia del polycosanol vs bezafibrato en pacientes con hiperlipidemias tipo II. Arch. Venezol. Farmacol. Ter. 1993; 12: 71-76.
17. Friedewald W. T., Levy R. I., Fredrickson D. S. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin. Chem. 1974; 18: 449-451.
18. Illingworth D. R. An overview of lipid-lowering drugs. Drugs 1988; 36: 63-71.
19. Arntz H.-R., Klemens U. H., Lang P. D., Vollmar J. Vergleich von Bezafibrat und Clofibrat bei Hyperlipoproteinenie Typ Iia und lib. Med. Klin. 1978,73: 1731.